ViroGates ASFRA:EP2 +2.84%44 Current Ratio is 3.82 as of Mar. 2026, which is 55% below its 10-year median of 8.58. GuruFocus rates FRA:EP2 with a GF Score™ of 44/100 and a GF Value™ of €0.90. The stock has 2 warning signs investors should review. Among 854 Medical Devices & Instruments companies, ViroGates AS ranks better than 68.15% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. ViroGates AS's current ratio for the quarter that ended in Mar. 2026 was 3.82.
ViroGates AS has a current ratio of 3.82. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for ViroGates AS's Current Ratio or its related term are showing as below:
FRA:EP2'
s Current Ratio Range Over the Past 10 Years
Min: 1.03 Med: 8.58 Max: 26.2
Current: 3.82
During the past 10 years, ViroGates AS's highest Current Ratio was 26.20. The lowest was 1.03. And the median was 8.58.
FRA:EP2's Current Ratio is ranked better than 68.15% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.475
vs FRA:EP2: 3.82
ViroGates AS (FRA:EP2) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
ViroGates AS Current Ratio Related Terms
ViroGates AS Current Ratio Historical Data
* Premium members only.
The historical data trend for ViroGates AS's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:EP2 vs ABT, SYK, MDT: Current Ratio Comparison
For the Medical Devices subindustry, ViroGates AS's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's Current Ratio distribution charts can be found below:
* The bar in red indicates where ViroGates AS's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ViroGates AS (FRA:EP2) has a Current Ratio of 3.82 as of Mar. 2026. This is 55% below median its historical median of 8.58. Over the past decade, ViroGates AS's Current Ratio has ranged from 1.03 to 26.20. According to the industry distribution chart, ViroGates AS ranks #272 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 31.9%.
Is ViroGates AS's Current Ratio too high?
ViroGates AS's current Current Ratio of 3.82 is 55% below median its 10-year median of 8.58. Over the past 10 years, this metric has ranged from a low of 1.03 to a high of 26.20. The Medical Devices & Instruments industry median Current Ratio is 2.48. ViroGates AS's value of 3.82 is 54.3% above this industry median. Based on the distribution chart, ViroGates AS ranks #272 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ViroGates AS has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #272 out of 854 companies for Current Ratio. This puts ViroGates AS in the upper half of its industry. The industry median Current Ratio is 2.48. ViroGates AS's value of 3.82 is 54.3% above this benchmark. Historically, ViroGates AS's own Current Ratio has ranged from 1.03 to 26.20 over the past decade. While the company's 10-year median is 8.58 vs. the industry median of 2.48, ViroGates AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.48, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ViroGates AS's current Current Ratio of 3.82 is 54.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current Current Ratio is 3.82, which is 55% below median its own 10-year median of 8.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
ViroGates AS (FRA:EP2) has a current Current Ratio of 3.82. The stock's GF Value™ is €0.90, compared to a current price of €1.45 — trading 61.1% above its estimated fair value. The current Current Ratio is 3.82, which is 55% below median its 10-year median of 8.58 and 54.3% above the Medical Devices & Instruments industry median of 2.48. ViroGates AS's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For ViroGates AS (FRA:EP2), the current Current Ratio is 3.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (FRA:EP2) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of €1.45 is trading 61.1% above its estimated GF Value™ of €0.90.
Key valuation signals for FRA:EP2:
Current Ratio: 3.82 (55% below median its 10-year median of 8.58)
GF Value™: €0.90 vs. price of €1.45 (61.1% above fair value)
Industry Position: 54.3% above the Medical Devices & Instruments median (#272 of 854)
No single metric tells the full story. See the FRA:EP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
44GF Score
Get the complete analysis for FRA:EP2
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EP2 has been successfully added to your 
